iBio Inc.

News

Recent Releases, Events & Media Assets

News

Latest News

iBio Selects Lead Candidate for its Fibrosis Therapeutics Program

NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”) announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic sclerosis and idiopathic pulmonary

Read Press Release

Latest Presentation

Upcoming Event

Dr. Carol Fengali-Bostwick presents at the Scleroderma Foundation – Courtesy of the Scleroderma Foundation, Inc.

Learn More

Additional